REGN Valuation

Regeneron Pharmaceuticals Inc

Add to Watchlist

Advanced Chart

563.000

+3.2(0.572%)1D

Overview
Forecast
Valuation
Earnings

REGN Relative Valuation

REGN's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average, adjusted by weights. If the market price exceeds this fair value range, REGN is overvalued; if below, it's undervalued.

Historical Valuation

Regeneron Pharmaceuticals Inc (REGN) is now in the Undervalued zone, suggesting that its current forward PE ratio of 14.25 is considered Undervalued compared with the five-year average of 16.26. The fair price of Regeneron Pharmaceuticals Inc (REGN) is between 662.99 to 913.65 according to relative valuation methord. Compared to the current price of 563.00 USD , Regeneron Pharmaceuticals Inc is Undervalued By 15.08%.

Relative Value

Fair Zone

662.99-913.65

Current Price：563.00

15.08%

Undervalued

14.25

Trailing

Forward

8.58

EV/EBITDA

Regeneron Pharmaceuticals Inc. (REGN) has a current EV/EBITDA of 8.58. The 5-year average EV/EBITDA is 11.48. The thresholds are as follows: Strongly Undervalued below 5.16, Undervalued between 5.16 and 8.32, Fairly Valued between 14.64 and 8.32, Overvalued between 14.64 and 17.79, and Strongly Overvalued above 17.79. The current Forward EV/EBITDA of 8.58 falls within the Historic Trend Line -Fairly Valued range.

10.07

EV/EBIT

Regeneron Pharmaceuticals Inc. (REGN) has a current EV/EBIT of 10.07. The 5-year average EV/EBIT is 12.31. The thresholds are as follows: Strongly Undervalued below 5.94, Undervalued between 5.94 and 9.13, Fairly Valued between 15.50 and 9.13, Overvalued between 15.50 and 18.69, and Strongly Overvalued above 18.69. The current Forward EV/EBIT of 10.07 falls within the Historic Trend Line -Fairly Valued range.

4.08

Regeneron Pharmaceuticals Inc. (REGN) has a current PS of 4.08. The 5-year average PS is 5.78. The thresholds are as follows: Strongly Undervalued below 3.40, Undervalued between 3.40 and 4.59, Fairly Valued between 6.97 and 4.59, Overvalued between 6.97 and 8.17, and Strongly Overvalued above 8.17. The current Forward PS of 4.08 falls within the Undervalued range.

15.21

P/OCF

Regeneron Pharmaceuticals Inc. (REGN) has a current P/OCF of 15.21. The 5-year average P/OCF is 15.63. The thresholds are as follows: Strongly Undervalued below 6.05, Undervalued between 6.05 and 10.84, Fairly Valued between 20.42 and 10.84, Overvalued between 20.42 and 25.21, and Strongly Overvalued above 25.21. The current Forward P/OCF of 15.21 falls within the Historic Trend Line -Fairly Valued range.

12.02

P/FCF

Regeneron Pharmaceuticals Inc. (REGN) has a current P/FCF of 12.02. The 5-year average P/FCF is 16.68. The thresholds are as follows: Strongly Undervalued below 2.91, Undervalued between 2.91 and 9.80, Fairly Valued between 23.57 and 9.80, Overvalued between 23.57 and 30.46, and Strongly Overvalued above 30.46. The current Forward P/FCF of 12.02 falls within the Historic Trend Line -Fairly Valued range.

Regeneron Pharmaceuticals Inc (REGN) has a current Price-to-Book (P/B) ratio of 1.97. Compared to its 3-year average P/B ratio of 3.37 , the current P/B ratio is approximately -41.63% higher. Relative to its 5-year average P/B ratio of 3.77, the current P/B ratio is about -47.87% higher. Regeneron Pharmaceuticals Inc (REGN) has a Forward Free Cash Flow (FCF) yield of approximately 6.64%. Compared to its 3-year average FCF yield of 5.01%, the current FCF yield is approximately 32.62% lower. Relative to its 5-year average FCF yield of 5.52% , the current FCF yield is about 20.19% lower.

1.97

P/B

Median3y

3.37

Median5y

3.77

6.64

FCF Yield

Median3y

5.01

Median5y

5.52

Competitors Valuation Multiple

The average P/S ratio for REGN's competitors is 5.58, providing a benchmark for relative valuation. Regeneron Pharmaceuticals Inc Corp (REGN) exhibits a P/S ratio of 4.08, which is -26.93% above the industry average. Given its robust revenue growth of 3.62%, this premium appears unsustainable.

P/S

P/E

EV/EBITDA

EV/EBIT

P/S

Revenue Growth

Market Cap

REGN.O

Regeneron Pharmaceuticals Inc

Alnylam Pharmaceuticals Inc

Performance Decomposition

Market capitalization of REGN decreased by 52.48% over the past 1 year. The primary factor behind the change was an increase in Revenue Growth from 3.55B to 3.68B.

The secondary factor is the Margin Expansion, contributed -6.24%to the performance.

Overall, the performance of REGN in the past 1 year is driven by Revenue Growth. Which is more sustainable.

3.62%

3.55B → 3.68B

Revenue Growth

-6.24%

40.38 → 37.86

Margin Expansion

-49.86%

28.42 → 14.25

P/E Change

-52.48%